Background Bipolar affective disorder (BPD) is a severe mood disorder with a prevalence of ∼ 1.5% in the population. The pathogenesis of BPD is poorly understood; however, a strong heritable component has been identified. Previous genome-wide association studies have indicated a region on 6q25, coding for the SYNE1 gene, which increases disease susceptibility. SYNE1 encodes the synaptic nuclear envelope protein-1, nesprin-1. A brain-specific splice variant of SYNE1, CPG2 encoding candidate plasticity gene 2, has been identified. The intronic single-nucleotide polymorphism with the strongest genome-wide significant association in BPD, rs9371601, is present in both SYNE1 and CPG2.
Background Bipolar affective disorder (BPD) is a severe mood disorder with a prevalence of ∼ 1.5% in the population. The pathogenesis of BPD is poorly understood; however, a strong heritable component has been identified. Previous genome-wide association studies have indicated a region on 6q25, coding for the SYNE1 gene, which increases disease susceptibility. SYNE1 encodes the synaptic nuclear envelope protein-1, nesprin-1. A brain-specific splice variant of SYNE1, CPG2 encoding candidate plasticity gene 2, has been identified. The intronic single-nucleotide polymorphism with the strongest genome-wide significant association in BPD, rs9371601, is present in both SYNE1 and CPG2.
Methods We screened 937 BPD samples for genetic variation in SYNE1 exons 14-33, which covers the CPG2 region, using high-resolution melt analysis. In addition, we screened two regions of increased transcriptional activity, one of them proposed to be the CPG2 promoter region.
Results and Conclusion
We identified six nonsynonymous and six synonymous variants. We genotyped three rare nonsynonymous variants, rs374866393, rs148346599 and rs200629713, in a total of 1099 BPD samples and 1056 controls. Burden analysis of these rare variants did not show a significant association with BPD. However, nine patients are compound heterozygotes for variants in SYNE1/CPG2, suggesting that rare coding variants may contribute significantly towards the complex genetic architecture underlying BPD. Imputation analysis in our own wholegenome sequencing sample of 99 BPD individuals identified an additional eight risk variants in the CPG2 region of SYNE1. Psychiatr Genet 27:81-88 Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc.
Introduction
Bipolar affective disorder (BPD) is a severe mood disorder characterized by episodes of mania and depression and has a lifetime risk of up to 1.5% (Merikangas et al., 2011) . Heritability estimates for BPD range between 79 and 83% (Kendler et al., 1996; McGuffin et al., 2003; Kieseppa et al., 2004; Barnett and Smoller, 2009 )and twin studies have found concordance rates of 40-70% for monozygotic twins (Burmeister et al., 2008) . Relatives of individuals with BPD are at increased risk for other psychiatric diseases such as schizophrenia and major depression, with which BPD shares phenotypic similarities (Craddock et al., 2005) . Linkage studies have suggested evidence for linkage between genetic markers and BPD on several chromosomal regions (Badner and Gershon, 2002; Segurado et al., 2003; Hamshere et al., 2005; Lambert et al., 2005; McQueen et al., 2005; Buttenschon et al., 2010; Greenwood et al., 2012) . Fine mapping of BPD genes using tests of linkage disequilibrium has been advanced by the HapMap Consortium (International HapMap Consortium, 2003; Song et al., 2010; Ceulemans et al., 2011) . Candidate gene studies have implicated several genes (Craddock and Forty, 2006) , although replication of findings has been slow (Chen et al., 2011; Dizier et al., 2012; Seifuddin et al., 2012) . No single causal genetic variant of BPD has been identified. However, there are many genes of major effect that seem to harbour variation that may increase susceptibility to BPD. Large samples sizes required to establish consistency of results and genome-wide association studies (GWAS) have presented significant evidence for several areas of association Djurovic et al., 2010; Cichon et al., 2011; Psychiatric GWAS Consortium Bipolar Disorder Working Group, 2011; Sklar et al., 2011; Yosifova et al., 2011; Lencz et al., 2013; Seifuddin et al., 2013; Gonzalez et al., 2014; Muhleisen et al., 2014; Xu et al., 2014) . There is replicated evidence for a genome-wide significant association in the ankyrin-3 (or ankyrin-G), ANK3 and the voltage-dependent L-type calcium channel α1C subunit, CACNA1C, genes in BPD (Schulze et al., 2009; Scott et al., 2009; Smith et al., 2009; Lett et al., 2011; Takata et al., 2011; Tesli et al., 2011; Dedman et al., 2012; Gonzalez et al., 2013; Zhang et al., 2013; Green et al., 2013b; Erk et al., 2014; Fiorentino et al., 2014) .
Linkage analysis identified an association in the chromosome 6q25 region with susceptibility to schizophrenia in a small study (Lindholm et al., 2001 ) and autism (Philippe et al., 1999) . One of the genes in this locus is SYNE1, encoding synaptic nuclear envelope protein-1 (also known as enaptin or nesprin-1). The SYNE1 singlenucleotide polymorphism (SNP) rs9371601, located in intron 16, passed the genome-wide significance threshold (P < 5.0 × 10 − 8 ) in large BPD GWAS Sklar et al., 2011) , followed by later replications (Psychiatric GWAS Consortium Bipolar Disorder Working Group, 2011; Green et al., 2013a; Xu et al., 2014) . However, this SNP has subsequently been shown to be only nominally significantly associated with BPD at P = 2.72 × 10 − 4 in the largest GWAS to date of 9784 BPD patients and 30 471 controls (Hou et al., 2016) . Nesprin-1 has been suggested to play several roles in cytoplasmic nuclear positioning, inner nuclear envelop function and Golgi structure maintenance (Gough et al., 2003) . Nesprin-1 is an exceptionally large spectrin family member and is expressed in a range of tissues, including the central nervous system. Expression of nesprin-1 is greatest in the cell bodies of Purkinje cells and in olivary body neurons of the lower brainstem. Mutations in SYNE1 lead to rare Mendelian phenotypes such as autosomal recessive arthrogryposis and autosomal recessive cerebellar ataxia 1 or ARCA1 (Dupre et al., 1993; Gros-Louis et al., 2007; Attali et al., 2009) . Furthermore, SNPs in SYNE1 have previously been noted in a metaanalysis of genome-wide association data of BPD and major depressive disorder (Liu et al., 2011) .
Like SYNE1, the ANK3 gene has been repeatedly implicated by GWAS to specifically increase susceptibility to BPD Sklar et al., 2011; Shinozaki and Potash, 2014) . Among a list of 180 genes, both SYNE1 and ANK3 were implicated in central nervous system development, neural projections, synaptic transmission, various cytoplasmic organelles and cellular processes and contributed towards 20-30% of the genetic load across six major neuropsychiatric disorders-attention deficit hyperactivity disorder, anxiety disorders, autistic spectrum disorders, BPD, major depressive disorder and schizophrenia (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013; Lotan et al., 2014) . Both the ankyrin-G and nesprin-1 proteins contain a highly conserved spectrin-binding domain, which is suggested to link proteins to the spectrin actin cytoskeleton. Nesprin-1 has been implicated to play a role in the function of ankyrin-G (Devarajan et al., 1996; Yang et al., 2007) . However, no evidence for ankyrin-G and nesprin-1 protein interaction has been shown to date.
The top GWAS SYNE1 SNP, rs9371601, was not found to be associated with structural brain alterations in BPD (Tesli et al., 2013) . The strongest nonsynonymous SNP in SYNE1, rs214976, associated with BPD is also present in the candidate plasticity gene 2, CPG2, a brain-specific splice variant of exons 16 to 33 of SYNE1, which was first characterized in the rat (Cottrell et al., 2004) . CPG2 encodes a protein present exclusively in the postsynaptic endocytotic zone of excitatory synapses and is upregulated by kainite-induced seizures in rat hippocampus dentate gyrus (Nedivi et al., 1993 (Nedivi et al., , 1996 Cottrell et al., 2004) . In this paper, we present data from an SYNE1/ CPG2 gene scan in BPD.
Here, we have screened SYNE1 exons 14-33 for variants in BPD samples using high-resolution melt (HRM) analysis, a PCR-based method for identifying DNA sequence variations by detecting changes in the melting of DNA duplexes. Human CPG2/SYNE1 cDNA sequence alignments with the human genome include an additional two SYNE1 exons (14 and 15), which were screened. In addition, the putative promoter region of CPG2 in intron 14 of SYNE1 and a potentially retained CPG2 intron corresponding to SYNE1 intron 33 (Cottrell et al., 2004) were also screened for polymorphisms. Nonsynonymous variants were subsequently genotyped in the University College London (UCL) BPD case-control sample.
Methods University College London clinical sampling
The UCL BPD cohort consists of 1099 individuals. These were sampled in two cohorts. The first cohort (UCL1) comprised 506 bipolar I cases Sklar et al., 2011) , whereas the second cohort (UCL2) comprised 409 bipolar I (69%) and 184 bipolar II cases (Dedman et al., 2012) . Among the UCL1 BPD cases were 143 with comorbid alcohol-dependence syndrome according to Research Diagnostic Criteria (RDC) (Lydall et al., 2011) . All UCL bipolar cases were interviewed by a psychiatrist using the lifetime version of the Schedule for Affective Disorders and Schizophrenia schedule (Spitzer and Endicott, 1977) , rated with the 90-item Operational Criteria Checklist (McGuffin et al., 1991) and fulfilled diagnostic criteria for bipolar disorder according to RDC (Spitzer et al., 1978) . The sample of 1056 normal controls comprised 672 screened controls who were interviewed with the initial clinical screening questions of the Schedule for Affective Disorders and SchizophreniaLifetime Version and selected on the basis of not having a family history of schizophrenia, alcohol dependence or BPD, for having no past or present personal history of any RDC-defined mental disorder and were not heavy drinkers, in addition to 384 unscreened British normal volunteers provided by European Collection of Animal Cell Cultures. All cases and controls were selected to be of UK or Irish ancestry as described previously (Datta et al., 2010) . UK National Health Service multicentre and local research ethics approvals were obtained and signed informed consent was provided by all participants. Genomic DNA was obtained from frozen whole-blood samples for cases and controls in UCL1 and from saliva samples for the cases in UCL2. DNA was extracted for all samples using methods that we have published previously (Pereira et al., 2011) and quantified with PicoGreen (Invitrogen, Paisley, UK) by fluorimetry.
High-resolution melt curve screening
A total of 937 BPD samples from UCL1 and UCL2 cohorts were scanned using HRM. Primers to amplify exons 14-33 within SYNE1, as well as for the putative CPG2 promoter region on SYNE1 intron 33 and a region of increased transcriptional activity on SYNE1 intron 14 can be found in Supplementary eTable 1 (Supplemental digital content 1, http://links.lww.com/PG/A178). Mutation screening was performed using Sensixmix HRM reagents (Bioline, London, UK), Accumelt HRM SuperMix (Quanta Biosciences, Gaithersburg, Maryland, USA) and Lightscanner Master Mix (BioFire Diagnostics Inc., Salt Lake City, Utah, USA) with the Roche LightCycler 480 (Roche, Burgess Hill, UK). Optimal HRM amplification conditions for each primer pair can be found in Supplementary eTable 1 (Supplemental digital content 1, http://links.lww.com/PG/A178).
Sequencing
Samples that showed altered or shifted HRM melt curve profiles were selected for sequencing. Sequencing was performed using the Big Dye terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Warrington, UK) on an ABI 3730xl DNA Analyser (Applied Biosystems) and analysed using the Staden Package (Staden, 1996) .
Genotyping and association analysis
To determine whether potentially aetiological nonsynonymous variants in SYNE1 increase susceptibility to BPD, fluorescent allele-specific PCR (KASPar) (LGC Genomics, Hoddesdon, UK) genotyping assays were designed. The three SYNE1 variants identified by HRM, rs374866393, rs148346599 and rs200629713, were KASPar genotyped on a LightCycler 480 RealTime PCR System (Roche) in all 1099 UCL1 and UCL2 BPD and control samples. Quality control to confirm the reproducibility of genotypes was performed as described previously (Dedman et al., 2012) . All these data were analysed to confirm Hardy-Weinberg equilibrium. Genotypic and allelic associations as well as burden analysis for rare single-nucleotide variants were determined using Fisher's exact tests. Significance values shown for all analyses are uncorrected for multiple testing and a cutoff significance value of P less than 0.05 was used.
Data analysis
Bioinformatic analysis to predict the effect of nonsynonymous variants on the function of SYNE1 and the proposed CPG2 region was carried out using the UCSC genome browser (http://genome.ucsc.edu), Polyphen-2 (http:// genetics.bwh.harvard.edu/pph2/index.shtml ) (Adzhubei et al., 2010) and SIFT BLink (http://sift.jcvi.org/www/SIFT_ BLink_submit.html ) (Kumar et al., 2009) . The protein reference for SIFT used was gi:220675590. The effect of a synonymous mutation on the exon was predicted using Genscript Rare Codon Analysis (http://www.genscript.com/ cgi-bin/tools/rare_codon_analysis). The codon adaptation index is a measure of synonymous codon usage bias where higher values indicate a higher proportion of the most abundant codons and possibly a higher chance of expression (Sharp and Li, 1987) . Project Hope (http://www.cmbi. ru.nl/hope/input) was accessed to analyse the protein structure of the mutations in CPG2 (Venselaar et al., 2010) .
1000 Genomes Phase3 data (1000 Genomes Project Consortium, 2010) were used alongside our own BPD whole-genome sequencing reference panel from 99 individuals (Fiorentino et al., 2014) to impute additional significantly associated variants in the CPG2 region of SYNE1 from the UCL Psychiatric Genomics Consortium 1 BPD samples (Sklar et al., 2008) . Imputation analysis was carried out using IMPUTE2 (Howie et al., 2009 (Howie et al., , 2011 and an association analysis was carried out using SNPTEST, version 2.5.1 using the frequentist association test (Marchini and Howie, 2010) . The Ensembl Variant Effect Predictor (McLaren et al., 2010) was used to predict the functional consequences of known and unknown variants and regulatory region variants were analysed in the ENCODE data (ENCODE Project Consortium, 2011). In our modest sample size, the frequency of nonsynonymous SNPs likely to affect protein function were summed across the cases and controls in a burden analysis to assess the overall impact of rare mutations in the gene (Knight et al., 2009) .
Results

High-resolution melt curve screening for variants Common single-nucleotide polymorphism detection
Following HRM analysis, several differently shaped melt curves were detected in SYNE1 (Table 1) . Two SNPs, rs4343926 and rs4331993, were found in the untranslated region between SYNE1 exon 14 and SYNE1 exon 15. It should be noted that rs4331993 occurred only in combination with rs4343926. Several samples with an abnormal melting profile were sequenced and variants rs62427038, rs34610829, rs17082709, rs214976 and rs17082701 were identified in exons 18, 22, 23, 26 and 27, respectively. Polyphen and SIFT predictions of how well nonsynonymous variants would be tolerated by the protein can be found in Table 1 . We found the synonymous variants, rs149670417 and rs138705766, using HRM gene scanning of SYNE1 exons 19 and 31, respectively, which induce an increase in the GC content from 46.23 to 46.09% and 57.74 to 58.26%, respectively (Genscript). Both variants lead to a minor decrease in the likelihood of the gene being expressed with a 0.01 reduction in the codon adaptation index from 0.66, where 1 represents 100% expression (Genscript).
It should be noted that two individuals were compound heterozygotes for rs62427038 and either rs149670417 or rs214976. Similarly, three individuals were compound heterozygotes for rs138705766 and rs17082701, whereas another individual carried mutant alleles for rs138705766, rs17082701 and rs4343926. Three individuals carried the variant alleles of rs4343926 as well as that of one of the following SNPs: rs17082709, rs17082701 or rs138705766. Therefore, nine patients are compound heterozygotes for rare variants in SYNE1/ CPG2, suggesting that there may be an additive effect of these base pair changes.
Genotyping of rare nonsynonymous variants HRM identified three rare nonsynonymous variants in the CPG2 region of SYNE1, which we genotyped in our case-control sample (Table 2 ). In SYNE1 exon 20, one BPD sample harboured the missense mutation, rs374866393, where the methionine residue would be larger and more hydrophobic than the wild-type threonine, which could result in a loss of hydrogen bonds and may disrupt correct protein folding (Project Hope). In SYNE1 exon 25, HRM screening identified that one BPD patient carried the G > A nonsynonymous variant, rs148346599, leading to a change from glutamic acid to lysine. The glutamate residue is negatively charged, whereas lysine is a larger residue with a positive charge, which might lead to repulsion with other residues as well as to the repulsion of ligands (Project Hope). We identified a third nonsynonymous variant in SYNE1 exon 29, rs200629713, which leads to an alanine to valine amino acid change and predicted to increase the size of the residue (Project Hope). Burden analysis does not show a significant difference between the number of rare variants in BPD cases and controls (Fisher's exact test, P = 1.00, d.f. = 1, n = 5963).
Imputed tests of association in SYNE1 in bipolar affective disorder Imputation analysis using IMPUTE2 and SNPTEST predicted that eight intronic or promoter regulatory region SNPs, located in both the SYNE1 and CPG2 transcripts, are significantly associated in the UCL BPD samples (Supplementary eTable 2, Supplemental digital content 2, http://links.lww.com/PG/A179). None of the imputed intronic or regulatory region variants were predicted to be in regions showing enrichment for the Table 1 Variants detected by high-resolution melt curve analysis H3K27Ac histone mark, which is the acetylation of lysine 27 of the H3 histone protein, often found near active regulatory elements (ENCODE) (ENCODE Project Consortium, 2011).
Discussion
We have screened exons 14-33 and the intronic regions 14 and 33 of SYNE1, overlapping the CPG2 transcript, using HRM in 937 BPD cases. Six synonymous and six nonsynonymous variants were identified. We genotyped three rare nonsynonymous variants in the UCL case-control sample of 2155 individuals, which were predicted to increase the size of the protein residue and may affect bending of the peptide chain. Unfortunately, we did not find a significant association between these three nonsynonymous variants in SYNE1 or CPG2 and BPD using burden analysis.
Nine samples carried more than one of the variants detected from scanning the SYNE1 gene. Thus, multiple variants may have a compound effect on protein function, similar to Parkin compound heterozygous mutations associated with Parkinson's disease (Malek et al., 2016) . To date, there is no replicated evidence that compound heterozygosity contributes towards BPD (Knight et al., 2009; Kember et al., 2015) or schizophrenia (Rees et al., 2015; Ruderfer et al., 2015) . However, additive and interactive combinations of rare coding variants in the ABCA13 gene have been suggested to contribute towards the complex phenotypes of both BPD and schizophrenia (Knight et al., 2009) . The compound heterozygous variants in SYNE1/CPG2 identified here reinforce the possibility of interactive effects of rare coding variants contributing significantly towards the aetiology of BPD.
Genetic variants in the SYNE1/CPG2 genes may impair CPG2 function or disrupt protein interaction in BPD patient carriers. Expression of the brain-specific SYNE1 splice variant, CPG2, was first discovered to be upregulated by kainite-induced seizures in the rat dentate gyrus (Nedivi et al., 1993) . The CPG2 protein contains several spectrin repeats and coils. Proteins with similar motifs often play a role in the organization of protein complexes (Burkhard et al., 2001) . The CPG2 protein localizes to the postsynaptic component of dendritic spines and shafts in human hippocampal neurons and regulates the rapid cycling of synaptic glutamate receptors by clathrin-mediated endocytosis (Loebrich et al., 2016) . Interestingly, CPG2-knockdown reduces glutamate receptor internalization and membrane insertion, increases the number of postsynaptic clathrin-coated vesicles and decreases dendritic spine size (Cottrell et al., 2004) . Synaptic glutamate receptor internalization in dendritic spines is dependent on F-actin physically binding to CPG2. Thus, CPG2 bound to F-actin functionally mediates postsynaptic endocytosis in the spine cytoskeleton necessary for vesicle uncoating (Loebrich et al., 2013) .
Furthermore, CPG2 appears to play a role in processes underlying long-term depression of neuronal synapses (Cottrell et al., 2004) . Altered glutamate levels in plasma, serum, brain tissue and cerebrospinal fluid; disrupted glutamate receptor function (Cherlyn et al., 2010) ; and decreased N-methyl-D-aspartate receptor expression and cellular plasticity cascades (McCullumsmith et al., 2007) have been associated with BPD. It would be interesting to characterize the functional effects of the variants reported here on CPG2-mediated glutamatergic N-methyl-D-aspartate receptor signalling (Cottrell et al., 2004) and AMPAR surface expression (Gong and de Camilli, 2008) .
In this study, we identified 12 genetic variants in SYNE1 and/or CPG2, which did not appear to play a significant role in susceptibility to BPD. However, imputation analysis of our whole-genome sequencing data identified eight SNPs that were associated significantly with BPD. The association between BPD and common variants in the SYNE1 gene warrants further investigation in a much larger sample. Further work is also necessary to characterize the functional effects of compound heterozygous rare variants on CPG2 and nesprin-1 proteins. 
